INDEX

Note: Page numbers in *italics* refer to Figures; those in **bold** to Tables.

Aboriginal Peoples Survey (APS), 385
adulteration, herbal medicines, 25
AEDs *see* antiepileptic drugs (AEDs)
alcoholic fatty liver disease (AFLD), 430
alkaloids
- classes, 202
- classifications, **203–4**
- description, 202
therapeutic uses, **205**
amplified fragment length polymorphism (AFLP) analyses, 35
amyloid precursor protein (APP), 357, 358
androgen receptor down-regulating agents (ARDAs), 286, 287, **288**, 288
anise (*Pimpinella anisum*), 175
antiasthma herbal medicine intervention (ASHMI), 67–8
anticancer drugs, pharmacophore models
androgen receptor down-regulating agents (ARDAs), 286, 287, **288**, 288
structure-activity relationships (SARs),
xanthones, 287–90, 289, 290
*Veratrum* species, 285, 285, 286
antiepileptic drugs (AEDs)
- anti-epileptic effects, 513–15, **513–15**
- anxiolytic effects, 520, **521**
carbamazepine, 507
diazepam, 511
*Gingko biloba*, 516
herbal medicines, 504, 506
memory impairment effects, 520, **522**, 523
MeSH search terms, 506
motor incoordination effects, **523**, 523–4
new, 512
pharmacodynamic actions, 512
pharmacokinetic interactions, 505
phenobarbitone, 511–12
phenytoin, 507, 510
phytomedicines, plasma concentrations, 507–9, **508–10**
sedative effects, 517–19, **518–19**
valproate, 510–11
anti-infective drugs, pharmacophore models
flavone M4753, 297–8, 298
non-nucleoside reverse transcriptase
inhibitors (NNRTIs), 297
pharmacophore-based screening, 298–9
anti-inflammatory drugs, pharmacophore
models
Chinese herbs, 293, 295
cyclooxygenase (COX) inhibitors,
290–292
herbal medicines, 293–4, 294
mPGES-1 inhibitors, 294, 296
“pharmacophore-based parallel
screening” (PS), 290
pharmacophore features, 294, 297
Prasaplat database (Prasaplat DB), 292,
292, 293
TCM Database@Taiwan, 294
anti-oxidants
biological and medicinal significance,
217–18
polyhydroxyphenols, 217, 218
polyhydroxystilbenes, 218–20
resveratrol, 220
Arab-Islamic herbal-based medicines
Arab and Muslim scholars, 143, 145
diet therapy, 146
disease and patient’s resistance, 146
evidence-based medicine and pharmacy,
143
Greco-Arab and Islamic medicine, 143,
144, 147
pharmacists/saydalaneh, 143–5
Prophet’s medicine, 142–3
simple and compound drugs, 146
stress hormones, 146
ARDAs see androgen receptor down-
regulating agents (ARDAs)
artemisinin, antimalarial drug, 18
ASHMI see asthma herbal medicine
intervention (ASHMI)
arthritis, 67–8, 93, 134, 156, 160, 165, 168,
171, 175, 176, 313, 566
atherosclerosis (AS) see ginsenosides,
atherosclerosis (AS)
atomic absorption spectroscopy (AAS)
heavy metals content determination, 32–3
toxic heavy metals determination, 22
atropisomerism, 332
Australian indigenous medicines
Acacia, 112–13
common plants, 109
cultural uses, 108–9
Customary Medicinal Knowledgebase (CMKb), 104
development and regulation, 116–17
Eremophila, 112, 112
Eucalyptus and Melaleuca, 113
food as medicine, 109
internal vs. external use, 107–8
Nagoya Protocol, 115
philosophy and knowledge transmission,
104–6
plant preparation methods, 109–11
Pterocaulon, 113
safety, 115–16
seasonal and other factors, 108
single vs. multiple plant ingredients, 108
Solanaceae, 113–14
traditional and Western medicine
integration, 117
treatment, 106–7
Australian Register of Therapeutic Goods (ARTG), 596
avocado-soybean
efficacy, 470, 473
osteoarthritis and rheumatoid arthritis,
470, 473
PIASCLEDINE® 300, 469
safety, 473
baicalein, 497, 497
berberine, 5
bioequivalence, 4
black cohosh, 540
black seed (Nigella sativa)
anti-allergic properties, 165
antidiabetic effects, 166–7
anti-inflammatory properties, 164–5
antimicrobial properties, 167
antioxidant activity, 164
antitumor properties, 165–6
cachexia, 133
Canada, regulations
advisory committees, 598
cultural belief system, 601
efficacy evidence, traditional medicines, 603
efficacy requirements, 602
food and drug, 598
Health Canada website, 594, 597
health claim, 600–601
Health Products and Food Branch Inspectorate (HPFBI), 598
Marketed Health Products Directorate (MHPD), 598
natural health products (NHPs), 597, 599
pharmacopoeial evidence, 603–4
qualifying claims, 604
rule, 599–600
safety evidence, traditional medicines, 603
safety requirements, 602
TCM, 601–2
traditional use, 602–3
cancer
black cohosh, 540
Echinacea, 541
fenugreek, 541–2
ginkgo biloba, 542
ginseng, 542–3
green tea, 543–4
herbal and complementary medicines, 537–8
herbal medicines, 537, 537
indole-3-carbinol (13C), 68
kava kava, 544
liquorice root, 544
milk thistle, 544–5
patients and physicians, 546–7
phytotherapy-drug interactions, 537
phytotherapy medicines, 536
St. John’s wort, 545–6
traditional Chinese medicine (TCM), 133
valerian, 546
cancer therapy
clinically useful phytocompounds, 395
effects, phytotherapeutics, 423–4
G. lucidum see Ganoderma lucidum
LEM see Lentinula edodes mycelia (LEM)
phytotherapeutic formulae
on NK cell cytotoxicity, 416–17
on NK cell numbers, 409, 410–415, 416
on QoL and survival period, 417, 418–22, 423
screening process, systematic review, 395–6, 396
capillary electrophoresis (CE), 31–2
capillary zone electrophoresis (CZE), 31
caprylic acid, 495, 495
carbamazepine, 507
cardiovascular diseases (CVDs)
drug development methods, 53–5
ginsenosides, 238
in vitro and in vivo constituents for efficacy, 56–7
phytomedicine efficacy, evaluation, 54, 55
natural product human clinical trials, 68
thiazolidinediones (TZDs), 432
cardiovascular drugs, pharmacophore models
farnesoid X receptor (FXR), 277–8
peroxisome proliferatoractivated receptor (PPAR), 270, 271–2, 274, 275
α-santonin, 270
carob (Ceratonia siliqua), 152
catechol moiety of piceatannol
anti-oxidant activity, 224
anti-oxidant/pro-oxidant activities, resveratrol and hydroxylated analogues, 224
DPPH* as model, lipid peroxyl radicals, 224
pro-oxidant activities, cytotoxicities, 224–6
CCIM see Central Council of Indian Medicine (CCIM)
CDSCO see Central Drugs Standard Control Organization (CDSCO)
CE see capillary electrophoresis (CE)
Central Council of Indian Medicine (CCIM)
Central Government, 618
Drugs and Cosmetics Act of 1940, 617
ISM systems, 617
manufactures, sale/distribution, 619
Central Drugs Standard Control Organization (CDSCO), 616
central nervous system (CNS) see antiepileptic drugs (AEDs)
chamomile (Chamomilla recutita), 174
chemical fingerprinting
capillary electrophoresis (CE), 31–2
chromatography, 29–31
hyphenated techniques, 33–5
spectroscopy, 32–3
chemokines, 67, 252, 253–4
chicory (*Cichorium intybus*), 155–6
China, regulations
  first-class protection, 605
  local administrative department, 606
  public health, 608–9
  second-class protection, 605
  State administrative departments, 604
  state examination and evaluation committee, 606
  traditional Chinese medicine, 607–8
Chinese Herbal Constituents Database (CHCD), 293–4
Chinese Herbal Medicine (CHM) databases, 270, 395, 397, 416–17, 424, 516
Chinese Natural Product Database (CNPD), 272
chromatographic fingerprint technique, 90
chromatography
gas chromatography (GC), 30
high-performance liquid chromatography (HPLC), 30–31
thin layer chromatography (TLC), 29–30
chronic bacterial prostatitis (CBP), 496
chronic lymphocytic leukemia (CLL), 75
Chronic Prostatitis Symptom Index (CPSI), 496
complementary and alternative medicine (CAM)
  herbal medicines see phytotherapy
  inflammatory disorders, 133
  profile, 11
  traditional Chinese medicine (TCM), 124
complementary medicine
  advantages, 561
  Australian profile, 10–12
  definition, 596
  international profile, 9, 9, 10
*Complementary Medicines in the Australian Health System*, 3
Constipation
  *A. vera*, 446
  CAM, 445
  *C. senna*, 447
  description, 444
  laxatives and prokinetic agents, 446
  pharmacological agents, 444
  pleiotropic effects, 445, 445
  *P. ovata*, 446
  *R. palmatum*, 446–7
  contamination of phytomedicines
  microorganisms and toxic heavy metals, test, 22, 23
  mycotoxins and endotoxins, 24
  pesticides and fumigation agents test, 22–4
  radiation, 24–5
  residual solvents test, 25
  sources, 22
Convention on International Trade in Endangered Species of Wild Fauna and Flora (CITES), 137
coriander (*Coriandrum sativum*), 174–5
cranberry
  clinical trials, 491–2
  *E. coli* and *H. pylori*, 491
  proanthocyanidin, 490, 490
  quinic acid, 491
  TMP-SMX, 490
  urogenital symptoms, 489
  UTIs, 488
Cree community of Eeyou Istchee (CEI), 378
curcumin
  anti-inflammatory and antioxidant, 354
  antimalarial, 359–60
  biological activity, 360
  carcinogenesis, 348
  clinical use, 346
  DMTC, 355
  EF-24, 353–4
  and GO-Y030, 351, 351
  methoxy group, 354
  NCI-60 DTP cell line screen, 353, 353
  in neurodegenerative diseases see neurodegenerative diseases
  Pabon method, 347–8
  structural features, 346
  tautomerism, 333
  tetrahydrocurcumin (THC), 349
  THC 26, 349
Customary Medicinal Knowledgebase (CMKb), 104
cytokines, 67, 164, 167, 170, 252, 253–4, 360, 381, 430, 432, 439, 473–7
CZE see capillary zone electrophoresis (CZE)
daptomycin, 486, 486
dates, 148, 151–2
delivery systems, herbal medicines
development, 96
guiding herbs, TCM, 92
liposomal herbal extracts, 91
nanocarriers, 94–5
pharmacokinetic research, 92
photosensitizers for photodynamic
therapy, 95–96
Phytosome® technology, 91
pulmonary delivery, 93–4
safety considerations, 92–3
surface modification of nanocarriers, 95
dengue, 496
dermatology, 70
device's dung (Ferula hermonis), 176
diabetes see also pharmacological screening
antidiabetic activity, plants, 378
clinical trials, 69–70
definition, 371
genetic predisposition, 371
non-insulin-dependent diabetes mellitus
(NIDDM), 371
North American pharmacopoeias, 372, 373–8
and obesity, community-based
participation, 386–7
pharmacological screening, 379, 384
prevalence, 370
syndromic importance value (SIV), 386
treatment, North American
pharmacopoeias, 372, 373–8
type 2 diabetes (T2D)
complications, 371, 372
genetic predisposition, 371
symptoms of, 372
syndromic importance value (SIV), 386
diazepam, 511
Dietary Supplement Health and Education
Act (DSHEA)
description, 626
FDA, 629
products, manufacturer, 629
DNA fingerprinting, 35
Doxil®, 93
DPIs see dry powder inhalers (DPIs)
Dragon’s Blood/Resina Draconis, 95
drugs from nature
animal models, 50
antitumor and antimicrobial drugs, 49
medicinal plants, 49
reverse pharmacology, 49–50
dry powder inhalers (DPIs), 94
DSHEA see Dietary Supplement Health and
Education Act (DSHEA)
Echinacea, 541
edible wild plants
chicory (Cichorium intybus), 155–6
fennel (Foeniculum vulgare), 156
gundelia (Gundelia tournefortii), 157
high mallow (Malva sylvestris), 157
Palestinian thyme (Majorana syriaca), 156
purslane (Portulaca oleracea), 157
EGCG see epigallocatechin gallate
(EGCG)
encephalic vascular accident see stroke
epigallocatechin gallate (EGCG)
cancer studies, 77–8
clinical studies, 76–7
HIV-1 infection, 78–80
metabolism, 76
pharmacokinetic studies, 74
polyphenon E, 75, 79–80
safety, toxicity, and pharmacokinetics,
75–6
structure, 74, 499
essential/volatile oils, 214
ethnobotany, 385–6
European Directive “European Traditional
Herbal Medicinal Products Directive
(THMPD) 2004/24/EC”, 195
European Guideline on the Investigation of
Bioequivalence, 4
European herbal medicines
evidenced-based medicine, 196
historical perspective, 184
“Hortus (‘Ortus’) sanitatis”, 194, 195
influences, 184, 187–93
medical practices and materia medica,
184
modern medicine, 194
orthodox medicine, 183–4, 185–6, 194
European Medicines Agency (EMA), 90
The European Organization for Research
and Treatment of Cancer Core
Quality of Life Questionnaire C30
(EORTC QLQ-C30), 408
European Union (EU), regulations authorization/registration, 613
Committee for Herbal Medicinal Products, 615
community herbal monographs, 615–16
eligibility criteria, herbal medicine, 610
herbal medicinal product, 609
herbal preparations, 609–10
herbal substances, 609, 612
medicinal products, 611
pharmaceutical quality, 614
Traditional Herbal Medicinal Products (THMP), 609
traditional-use registration, 612–13
farnesoid X receptor (FXR)
Eriobotrya japonica, 279, 283
Ganoderma lucidum, 277, 279, 280–281, 282
ligand-based pharmacophore models, 283–4, 284
structure-based pharmacophore model, 277, 278
triterpines, 279, 282, 282–3
fatty acids
essential fatty acids, 213
lipids, 212
polyunsaturated fatty acids, 213, 213
saturated and unsaturated, 212, 213
fatty liver disease (FLD)
AFLD, 430
AMPK pathway, 431
C. sinensis, 437–8
Ginseng, 437
lipid droplet (LD), 430
lipid homeostasis, 430–431
manifestation, 431, 431
metformin, 432
NAFLD, 430
pharmacological intervention, 432
PPARα, 431
Silybum marianum, 433, 436
SREBP-1c, 431
T. foenum-graecum, 438
treatment, herbal medicines
activities, 433, 434–5
pleiotropic effects, 433, 436
TZDs, 432
Federal Trade Commission (FTC), 627, 631
fennel (Foeniculum vulgare), 156
fenugreek (Trigonella foenum-graecum), 167–8, 541–2
figs (Ficus carica), 147–8, 153
First Nations and Inuit Regional Health Survey (FNIRHS), 385
Five Phase Theory of Systemic Correspondence, 125–6, 126, 126
flavokawains, 316, 316–17
flavonoids
classes, 207
classifications, 208
plant sources and uses, 208
structures, 206
food therapy, Greco-Arab and Islamic medicine
carob (Ceratonia siliqua), 152
dates, 148, 151–2
figs (Ficus carica), 147–8, 153
garlic (Allium sativum) and onion (Allium cepa), 154
honey, 148–9
melon, 148
olive oil, 149–51
plants
medicinal see medicinal plant(s)
wild see edible wild plants
pomegranate (Punica granatum), 153–4
formulations, herbal medicines
barriers, physicochemical and biological properties, 89–90
quality and safety assurance, 90
therapeutic efficacy, 90–91
free fatty acids (FFAs), 430
FXR see farnesoid X receptor (FXR)
galegin, 379
gamma-aminobutyric acid (GABA), 5, 174, 268, 301, 314, 315, 512, 513, 516, 517, 520, 523
Ganoderma lucidum
ASHMI, 67
chemical structures, 279, 280–281
description, 404
EORTC QLQ-C30, 408
Ganopoly treatment, 404, 408
HADS, 408
on NK cells, 404, 405–6
pharmacological evaluation, 277, 279
on QoL and survival condition, 404, 407, 408
questionnaires, 408
12 week treatment, cancer, 408
garlic (Allium sativum) and onion (Allium cepa), 154, 172
gas chromatography (GC), 30
gastroenterology, 70–72
GC see gas chromatography (GC)
genomics, 36
germacrone, 91
German herbal medicine, 127
G. glabra, 438–9
ginger (Zingiber officinale), 176, 494, 494
ginkgo biloba, 542
ginseng, 136–7, 437, 542–3
Ginsenosides, atherosclerosis (AS)
anti-angiogenesis effects, 257
anti-atherosclerotic effects
ApoE-deficient mice, 244
en face evaluation method, 244
in vivo studies, 240, 241–3
anti-oxidant activity, 251–2
anti-platelet effects, 257
anti-vascular inflammation
adhesive molecules, 253
chemokines, 254
inflammatory cytokines, 253–4
lipid mediators, 253–4
NF-κB activity, 254–5
biological effects, 240
chemical diversity and distribution, 238–40
chemical structures, 238, 239
cholesterol-lowering drugs, 238
composition, chemical differences, 238, 240, 240
Ginsengs and Ginsenosides, 237–8
herbal medicines, use, 236–7
in vitro studies, 244, 245–50
Panax species, 237
publications, 237, 237
regulation of blood lipid profile, 244, 251
vascular endothelial cells, 255–6
vascular smooth muscle cells (VSMCs), 256
glucose-stimulated insulin secretion (GSIS), 380
glycosides
cardiac glycosides, 209
C-glycosides and S-glycosides, 208
classes, 208, 209
eamples, 210
glycyrhetinic acid (GA), 95
glycyrrizin (GL), 95
good manufacturing practices (GMP)
complaints, 595
distribution records, 595
FDA, 595
guidelines, 595
hygiene, 594
instructions and procedures, 594
manufacturing processes, 594
recall systems, 595
records, 594–5
validation, 594
WHO, 595
gossypol
anticancer, 338
antifertility, 337, 338
antimalarial activity, 345
antiviral activity, 341–3
apogossypol, 340
atropisomerism, 332
BI-97C1, 341
biological activity, 346
botanical sources, 330, 341
in cottonseeds, 330, 331
curcumin, 331–2
growth inhibitory activity, 338–9, 339
HIV activity, 343–4
mitochondrial-mediated mechanism, 340
partial hydrolysis, gossypol bis-Schiff’s bases, 336
Schiff’s bases, 339, 344, 345
stereoisomerism, 332
tautomerism, 333, 335
GO-Y030, 351–2
green tea (Camellia sinensis), 437–8
and bortezomib, 543–4
constituents, 437, 543
epigallocatechin gallate (EGCG), 73–4, 437, 543
liver diseases, 438
polyphenolic catechin structures, 74
polyphenolic compounds, 73
ultraviolet-induced events protection, 70
Gui Zhi Fu Zi Tang, 128, 130
gundelia (Gundelia tournefortii), 157

Harpagophytum procumbens
- efficacy, 469
- proinflammatory gene expression, 468
- safety, 469, 470

Health Canada website, 594, 597
Health Products and Food Branch Inspectorate (HPFBI), 598
herbal materia medica (HMM), 573
herbal medicine (HM) see also delivery systems, herbal medicines
Chinese herbal medicine, 7
constipation treatment, 445
and dietary supplements, 561
in Europe see European herbal medicines
fatty liver treatment, 433
formulations
- barriers, physicochemical and biological properties, 89–90
- quality and safety assurance, 90
- therapeutic efficacy, 90–91
- health and well-being, 559–60
- QUM relevance, 556–8
- and traditional Chinese medicine, 126–30
herbal substitution, 25
herb drug research
- in vitro assays, 50–51
- in vivo assays, 51–2
high mallow (Malva sylvestris), 157
high-performance liquid chromatography (HPLC), 24, 30–31
high-performance TLC (HPTLC), 30
high-throughput next-generation sequencing (HT-NGS) technology, 36
HIV-1 infection, 79–80
honey
- anti-inflammatory effects, 149
- antimicrobial effects, 149
- anti-oxidant activity, 149
- healing effects, 148
- lung disease, 149
Hospital Anxiety and Depression Scale (HADS), 408
HPLC see high-performance liquid chromatography (HPLC)
HT-NGS technology see high-throughput next-generation sequencing (HT-NGS) technology

Huangdi Neijing, 123
Huang Qin Tang (traditional Chinese medicine), 134–6
hydroxystilbenes, 225
hyper-homocysteinemia (Hcy), 256
hypericin, 95–6
hyphenated techniques
- CE-MS, 35
- GC-MS, 33–4
- HPLC-NMR, 34
- LC-MS, 34–5
Iberogast®, 71
India, regulations
- CCIM, 616–19
- CDSCO, 616
indole-3-carbinol (13C), 68
infectious diseases
- antimicrobial agents, 487
- antimicrobial drugs, 484–5
- baicalein, 497, 497
- cranberry see cranberry
- daptomycin, 486, 486
- dengue, 496
- high throughput (HT) screening, 487
- HIV/AIDS, 484
- linezolid, 485, 485
- MRSA, 498–9
- mupirocin, 485, 485
- nalidixic acid, 487, 487
- natural products, 486–7
- prevention and treatment, 488
- SARS, 497–8
- synergistic and additive effects, antibiotics, 496
- tetracycline, 485, 485
- WHO, 484
inflammatory bowel disease (IBD)
- clinical response and remission, 70–71
- Iberogast, usage, 71
- peppermint extracts, usage, 71
- TXYF clinical trials, 72
inflammatory conditions
- avocado-soybean, 469–73
- in Europe, 464
- Harpagophytum procumbens, 468–9
- NSAIDs, 465
- PAIDs, 465, 466
- Salix, 465, 467–8
inhaled phytotherapies, 93–4
Integrative Chinese and Western medicine (ICWM), 497–8
intellectual property (IP)
    communities and governments, 587–8
    Convention, Biological Diversity, 588–9
    copyright, 574
    HHM, 573
    industrial designs, 574, 586
    laws, industrialized jurisdictions, 575
    legal principles, 574
    phyto-industry, 575
    plant variety protection, 586
    plant variety rights, 574
    regulatory exclusivity and restricted third-party access, 585–6
    trademark/branding, 586
    trademark registrations, 574
    trademarks and design registration, 576
    trade secrets, 574, 575–6, 585
    traditional knowledge, 588
    TRIPS Agreement, 575
intercellular cell adhesion molecule-1 (ICAM-1), 253
International Prostatic Symptom Score (IPSS) questionnaires, 496
International Regulatory Cooperation for Herbal Medicines (IRCH), 632
international regulatory status
    alkaloids, 593–4
    Australia, 596–7
    Canada see Canada, regulations
    China see also China, regulations
administrative department of public health, 607–8
    period of protection, 607
    protection types, 605
    registration, 608
    State Administration of Traditional Chinese Medicine website, 604–5
country law sources, 594
European Union (EU) see European Union (EU), regulations
good manufacturing practices (GMP), 594–5
India, 616–19
Japan, 619–22
laws, health products, 593
United Kingdom, 622–5
United States, 625–31
Wikipedia, 593
International Union of Pure and Applied Chemistry (IUPAC), 269
Inuulitsivik midwifery service and education program, 385
in vitro models, herb drug research
    dimethylsulfoxide (DMSO), 51
    extract fractions, 51
    phytomedicine efficacy, cardiac effects, 55
    solubility, 51
in vivo models, herb drug research
    drug doses, 51–2
    herbal extract, administration, 52
    phytomedicine efficacy, cardiac effects, 54
IP see intellectual property (IP)
irritable bowel syndrome (IBS)
    CAM therapies, 440
    C. longa, 443
    C. reticulate, 443–4
    C. scolymus, 441–2, 442–3
    pathophysiological mechanisms, 439
    pleiotropic effects, 440–441, 441
    QOL, 441
treatments, 439–40
Japan, regulations
    and Chinese medicines, 620
    herbal medicines, 620
    kampo medicine, 619
    Pharmaceutical Affairs Law, 619–20
    post-marketing surveillance, 622
    safety and efficacy, 621
    traditional medicine indigenous, 619
Kahnawake Schools Diabetes Prevention Project, 385
kampo medicine, 32, 619, 620, 621
kava (Piper methysticum)
    anti-cancer effects
        flavokawain A, 316, 316–17
        flavokawain B, 316, 317
    anti-psychotic effects
        anti-anxiety property, 314
        gamma-aminobutyric acid (GABA) receptors, 314–15
        kavain, 315
        structure activity relationship (SAR) analysis, 315
    anxiety and insomnia, treatment, 312
    extraction, 312–13
    hepatotoxicity
kava (Piper methysticum) (cont’d)
cyclooxygenase enzyme activity, 320–321
cytochrome P450 enzyme activities, 318–19, 319
hepatic inflammatory responses, 320
hepatic mitochondria, damage of, 321–2
hepatic transporters, 321
kava extracts, 318
liver glutathione, 319–20
pipermethistine and flavokawain B, 318
kavalactones, 313, 313
side effects, 317
therapeutic applications, 314, 314
kavain, 313, 313, 315, 320–322
kava kava, 544
kavalactones, 8, 313, 313–16, 318–22, 544
kharob, 152
khella (Ammi visnaga), 168
Kudzu root, 4
lavender flower, 5
lavender oil, 5
Lentinula edodes mycelia (LEM)
as Chinese herbal medicines (CHMs), 397
description, 397
lentinan treatment, 404
mushroom-derived extract, 396–7
on NK cells, 397, 398–9
on QoL and survival condition, 397, 400–403, 404
linezolid, 485, 485
Ling-Zhi see Ganoderma lucidum
lipid homeostasis, 430–431
lipid mediators, 253–4
lipids, definition, 212
liquid chromatography/mass spectroscopy (LS/MS), 134
liquorice root, 544
malva, 157
Management Advisory Committee (MAC), 598
marjoram (Origanum majorana), 171
Marketed Health Products Directorate (MHPD), 598
mass spectrometry (MS), 33
matrix-assisted laser desorption/ionization (MALDI), 36
maximal electroshock seizures (MES), 300–301, 302
medicinal effects, dietary intake
anti-oxidants, 217–20
omega-3 long chain fatty acids and derivatives, 220–223
medicinal plant(s)
anise (Pimpinella anisium), 175
black seed (Nigella sativa) see black seed (Nigella sativa)
chamomile (Chamomilla recutita), 174
coriander (Coriandrum sativum), 174–5
devil’s dung (Ferula hermonis), 176
fenugreek (Trigonella foenum-graecum), 167–8
garlic (Allium sativum) and onion (Allium cepa), 172
ginger (Zingiber officinale), 176
khella (Ammi visnaga), 168
marjoram (Origanum majorana), 171
milk thistle see milk thistle (Silybum marianum)
nettle (Urtica dioica), 172–3
peppermint (Mentha piperita), 173–4
rocket (Eruca sativa), 172
rosemary (Rosmarinus officinalis), 175–6
sage (Salvia officinalis), 168
tayun (Inula viscose), 172
medicinal plant preparation methods
Aboriginal medicine preparations, 110
decoction, 110, 111
direct crushing (application), 110
emollient, 110
infusion, 109
maceration, 110
roasting, 110
smoking, 110
Medicines and Healthcare products
Regulatory Agency (MHRA)
Certification Mark, 623
rules and regulations, 622
melon, 148
Meriva®, 92
metabolomics, 6, 36–7, 90
metformin, 432
Methicillin-resistant Staphylococcus aureus (MRSA)
description, 498
EGCG, 498–9, 499
microemulsion electrophoretic capillary chromatography (MEEKC), 32
milk thistle (Silybum marianum)
active compounds, 168–9
alcoholic liver disease, 170–171
detoxifying and hepatoprotective effects, 169–70
liver regeneration, 171
silymarin and silybin, 169, 433, 436
monocyte chemoattractant protein-1 (MCP-1), 254
MRSA see Methicillin-resistant Staphylococcus aureus (MRSA)
mupirocin, 485, 485
nalidixic acid, 487, 487
nanocarriers
drug/gene delivery, 94–5
surface modification, 95
natural cytotoxicity receptors (NCRs), 395
natural health products (NHPs)
in Canada, 597
commercial sale, 598
health claims, 599
MHPD, 598
regulatory pathway, 600–601
safety and efficacy, 599
natural killer (NK) cells
anticancer immunomodulation, 395
G. lucidum, 404, 405–6
LEM effects, 397, 398–9
phytoterapeutic formulae, effects
cell cytotoxicity, 416–17
cell numbers, 409, 410–415, 416
QoL and survival period, 417, 418–22, 423
natural product human clinical trials
asthma, 67–8
cancer, 68
cardiocvascular disease, 68
dermatology, 70
diabetes, 69–70
gastroenterology, 70–72
green tea, 73–4
rheumatoid arthritis (RA), 66–7
viral infections, 72–3
Natural Standard Herbal Pharmacotherapy, 1
nebulization, injectable TCM solutions, 93
nettle (Urtica dioica), 172–3
neurodegenerative diseases
APP, 357
CNB-001, 358
description, 357
in vitro and in vivo studies, 357
neurological drugs, pharmacophore models
Chinese herb, Semen ziziphi spinosae (suzaon), 301, 303
dispyrin, chemical structures, 303, 305
Ebelin lactone isomers, 302, 304
H₃ antagonist pharmacophore model, 303, 304
maximal electroshock seizures (MES) and RotoRod tests, 300–301, 302
morphinans and isoquinolines, 299–300, 301
RMS<0.200, pharmacophore mapping, 300, 302
NHPs see Natural health products (NHPs)
NIDD see non-insulin-dependent diabetes mellitus (NIDDM)
n-3 monounsaturated fatty acid analogues, docking, 229
nonalcoholic fatty liver disease (NAFLD), 430–432, 437, 438
non-insulin-dependent diabetes mellitus (NIDDM), 371
non-nucleoside reverse transcriptase inhibitors (NNRTIs), 297
North American pharmacopoeia plants
antidiabetic and antiobesity activity, plants, 378
diabetes treatment, 372, 373–8
traditional knowledge (TK) targeted approach, 372
nuclear magnetic resonance (NMR) spectroscopy, 33
obesity see also pharmacological screening
antidiabesity activity, plants, 378
and diabetes see diabetes prevalence, 370–371
olive oil, 149–51
omega-3 long chain fatty acids, 220–223
“omics” technology
genomics and transcriptomics, 36
metabolomics, 36–7
proteomics, 36
orthodox medicine (OM), in Europe, 184, 185–6
orthogonal projections to latent-structures-discriminant analysis (OPLS-DA), 37
Pabon synthesis of curcumin, 347–8
Palestinian thyme (Majorana syriaca), 156
Palmar–Plantar skin reactions, 93
partial least square discriminant analysis (PLS-DA), 4
patents
allowance and grant, 579
examination and classification, 579, 580–584
extension, 579
filing, 579
IP assets, 576–77
jurisdictions, 577
ownership, 578
phyto-inventions, 577
searching, 578
traditional medicinal plants, 587–9
TRIPS jurisdictions, 577–8
“worldwide” patent database, 587
peppermint (Mentha piperita), 173–4
peroxisome proliferator activated receptor (PPAR)
chemical structures, 270, 271–2
luciferase reporter gene assays, 270
neolignans
dieugenol, magnolol, and
tetrahydrodieugenol, structures, 270, 272, 273, 274
on human PPARγ-mediated reporter
gene transactivation, 272, 274
oleanonic acid, 272, 275
pan-PPAR agonism, 272
partial agonists, 272, 275
PPARα, lipid catabolism, 431
PPARδ selectivity, 273, 276, 277
structure-based pharmacophore model, 270, 273, 278
subtype gamma (γ), 270, 271–2, 274, 275
subtypes, 272–3, 277
thiazolidinediones, 270
in treatment of metabolic diseases, 270
(S)-tryptophanbetaxanthin and
berberrubine, 272–3, 276
pharmacognosy
bioequivalence, 4
description, 3
pharmacokinetic research, delivery
systems, 92
pharmacological screening
diabetes
advanced glycation end-products (AGEs), 381
antidiabetic activity, CEI pharmacopoeia, 382–3
antioxidant activity, 381
in vitro screening, primary/secondary
antidiabetic activity, 380–381
in vivo animal models and in vitro
bioassays, 380
obesity
botanical extracts, activity of, 384
indirect activity, complications, 384
natural antiobesity preparations, 384
pancreatic lipase, 384
pharmacophore-based parallel screening (PS), 290
pharmacophores
IUPAC definition, 269
models
for anticancer drugs, 285–90
for anti-infective drugs, 297–9
for anti-inflammatory drugs, 290–297
of cardiovascular drugs, 270–84
CYP1A2 inhibitory activity, 305–6, 308, 309
of Evo compounds, 305, 307
Hopyo-1 and Hopyo-1m model, 305, 307
for neurological drugs, 299–305
of PDE5 binding site, 305, 306
pharmacophoric features, 269, 269
in silico highthroughput screening, 268–9
phenobarbite, 511–12
phenytoin, 507, 510
physiologically based pharmacokinetics (PBPK), 92
phyto-anti-inflammatory drugs (PAIDs)
efficacy, 475, 478
oral, 476
safety, 475–6, 478
topical, 477–8
unsaturated fatty acids, 475
phytochemicals
alkaloids, 201–2, 203–4, 205
amylopectin, 215
amylose, 215, 216
cellulose, 216
essential/volatile oils, 214
fatty acids, 212–14
flavonoids, 205–7, 208
glycosides and saponins, 208–9
inulin, 216
mucilage, 217
phytosterols, 209–12
polysaccharides, 215
starch, 215–16
terpenes, 214, 215, 215
phytomedicines
adulteration, 39
adverse effects, 39
chemical fingerprinting, 29–35
constituents, 19
definition, 18
DNA fingerprinting, 35
in vitro and in vivo evidence
cardiovascular diseases, 56–7
stroke, 59
integrated “omics” analysis, 38
macroscopic evaluation, 27
microscopic evaluation, 27, 29
“omics” technology, 36–7
physicochemical analysis, 29
quality control/assurance see quality
control/quality assurance (QC/QA)
standardization, 38
Phytosome® technology, 91
phytosterols
chemical structures, 212
cholesterol, 210, 211
source, 210
stanols, 210, 212
sterols, 210, 211
phytotherapeutic formulae, cancer therapy
on NK cell cytotoxicity, 416–17
on NK cell numbers
formulae, effects, 409, 410–415
Radix astragali and Radix codonopsis, 416
SFI, 409, 416
on QoL and survival period
formulae, effects, 417, 418–22, 423
Karnofsky scores, 417
SFI, 417, 423
Shenqi mixture, 423
phytotherapy
clinical research
Chinese herbal medicines, 7
efficacy, 6–7
food nutrition and translational research, 7–8
community-based participation, 385–7
definition, 593
international trend, complementary medicines, 2–3
pharmacological screening see pharmacological screening
pharmacopoeia see North American pharmacopoeia plants
preclinical research
pharmacognosy and quality standardization, 3–4
pharmacological studies and bioactive compound identification, 4–5
proteomics and metabolomics, 5–6
safety, 8–9
phytotherapy-drug interactions
CYP3A gene, 539
pharmacodynamic, 538
pharmacokinetic, 538
PXR, 539
PIASCLGEDINE® 300, 469, 470, 473
plasminogen activator inhibitor-1 (PAI-1), 256
pMDIs see pressurized metered dose inhalers (pMDIs)
polyhydroxyphenols, 217, 218
polyhydroxystilbenes, 218–20
polyphenon E
description, 75
HIV-1 infection, 79–80
polysaccharides, 94, 95, 155, 157, 163, 215, 216, 397, 404, 408, 433, 437, 446, 542, 596
pomegranate (Punica granatum), 153–4
PPAR see peroxisome proliferator activated receptor (PPAR)
Prasaplai database (Prasaplai DB), 292, 292, 293
pregnane X receptor (PXR), 539
pressurized metered dose inhalers (pMDIs), 93–4
pro-angiogenesis therapy, 257
proanthocyanidin, 490, 490
processing, herbal preparations, 26–7
proteomics, 5–6, 36
pulmonary delivery, herbal medicines, 93–4
purslane (Portulaca oleracea), 157
PXR see pregnane X receptor (PXR)

Qi life force
strengthening, 12
yin and yang, 124, 125
QoL see quality of life (QoL)
quality assurance criteria, herbal medicines, 90
quality control/quality assurance (QC/QA) adulteration, 25
assessments, phytomedicines, 20, 21, 28
chemical fingerprinting, 29–35
contamination, 22–5
contents and standardization, 26
description, 19
DNA fingerprinting, 35
good agricultural and collection practices (GACP), 20–22
macroscopic evaluation, 27
microscopic evaluation, 27, 29
physicochemical analysis, 29
processing, 26–7
stability, 26
substitution, 25
quality of life (QoL)
cancer patients
EORTC QLQ-C30, 408
G. lucidum extract effects, 404, 407, 408–9
lentinan and LEM extract, 397, 400–403, 404
phytotherapeutic formulae, effects, 417, 418–22, 423
CBP patients, 496
IBD patients, 71
quality use of medicines (QUMs)
advantages, complementary medicines, 560, 561
adverse drug reaction reporting, 569
adverse reactions, 563–4, 564
allergy, 565
Australian survey, 560
complementary medicines, 558–9
education and training, 568
effectiveness, 565–6
European survey, 560
framework, herbal therapies, 556–7
German users, 559
global market, herbal medicines, 562
GMP, 558
health literacy, 566–7
herbal medicines and dietary supplements, 561
high-quality objective information, 567–8
information sources, consumers, 567
interactions, 564–5
judicious use, 554–5
NPS Medicinewise survey, 560
paradigm, 555–6
principles and practices, 554
promotion and advertising, herbal medicines, 567
safe and effective use, 555, 563
safe formulation, 565
selection, 555
shared decision making, 569–70
WHO, 557
quantitative NMR (qNMR), 33
quercetin, 5
QUMs see quality use of medicines (QUMs)

RA see rheumatoid arthritis (RA)
Raman spectroscopy, 32
randomly amplified polymorphic DNA (RAPD) analysis, 35
Ren Shen (Ginseng), 127
resveratrol, 52, 68, 160, 218, 220, 224, 226
reverse pharmacology, 49–50
rheumatoid arthritis (RA), 66–7
rocket (Eruca sativa), 172
rosemary (Rosmarinus officinalis), 175–6
RotoRod tests, 300–301, 302
sage (Salvia officinalis), 168
Salix
adverse events, 467
chronic toxicity, 468
efficacy, 467
safety, 467–8
willow bark, 467
Salmonella enteritidis and Campylobacter jejuni, 495–6
Sanguis Draxonis, 95
saponins, 209, 210
Schiff’s bases, 339
severe acute respiratory syndrome (SARS) ICWM, 497–8
TCM, 497
Shenqi Fuzheng Injection (SFI)
functionality, NK cytotoxicity, 416–17
NK cell numbers
clinical trials, 416
description, 416
Radix astragali and Radix codonopsis mixture, 416
and Shenqi mixture, 417, 423
Silybum marianum, 433, 436
spectroscopy
atomic absorption spectroscopy (AAS), 32–3
mass spectrometry (MS), 33
nuclear magnetic resonance (NMR) spectroscopy, 33
vibrational spectroscopy, 32
sterol regulatory element-binding protein-1c (SREBP-1c), 431
stilbenes, 218
St. John’s wort, 5, 545–6
stroke
acute, 55
chronic, 55
in vivo models, 58
induction method, animals, 58, 58
phytomedicines, in vitro and in vivo efficacy, 59
structure-activity relationship (SAR) studies, 223, 226–9, 287–90, 289, 290, 315
sulfur fumigation, 23
Sulindac® combination trial, 66
syndromic importance value (SIV), 386
systems biology approach, 92
tautomerism
curcumin, 333, 336
gossypol Schiff’s bases, 333, 335
gossypol tautomers, 333, 334
tayun (Inula viscose), 172
TCM see Traditional Chinese Medicine (TCM)
TCM Database@Taiwan, 294
terpenes
classifications and characteristics, 214, 215
isoprene, 215
Textbook of the Yellow Emperor, 122–3
T. foenum-graecum, 438
Therapeutic Goods Administration (TGA)
website, 596–7
thiazolidinediones (TZDs), 432
thin layer chromatography (TLC), 29–30
thunder god vine on RA, 66
traditional Chinese medicine (TCM), 497
complementary and alternative medicine, 124
description, 1–2
diabetes treatment, 2
diagnosis, 125
Five Phase Theory of Systemic Correspondence, 125–6, 126, 126
Ginseng see Ginseng and herbal medicine balance, 127
characteristics, herbs, 127, 128, 129
diagnosis, 126
extracts, 127
formulations, 127
Gui Zhi Fu Zi Tang, 128, 130
single agent therapies, 127
Huangdi Neijing, 123
Huang Qin Tang see Huang Qin Tang phytotherapy development cancer care, 133
common herbs, 131, 132
diabetes, 132
inflammatory disorders, 133
issues, 130–131
quality assessment, 90
syndrome patterning, 138
Taoist philosophy, 124
Textbook of the Yellow Emperor, 122–3
theories, 2
Tong Xie Yao Fang (TXYF), 72
Treatise on Cold Damage Disorders, 123
treatment principles, 440
and Western medicine, 124–5
Xin Xiu Ben Cao, 123
yin and yang, 124, 125
traditional herbal medicinal products (THMP), 609
Traditional Herbal Registration (THR), 622–3
traditional knowledge (TK) targeted approach, 372
traditional medicine, definition, 102
transcriptomics, 36
translational medicine, 78–9
Valerian, 546
Valproate, 510–511
Vascular cell adhesion molecule-1 (VCAM-1), 253
Vascular endothelial cells, 255–6
Vascular smooth muscle cells (VSMCs), 256
Vibrational spectroscopy, 32
Viral infections, 72–3

Western herbal medicine, 1, 429, 433, 448, 570
WHO see World Health Organization (WHO)
WHO Traditional Medicine Strategy (2014–2023), 2
World Health Organization (WHO), 90
IRCH, 631–2
leading causes of death, 2011, 53, 53
QUMs, 557
traditional medicine definition, 102
traditional medicines promotion, 2
working group meeting, 632–3

Xin Xiu Ben Cao (first official pharmacopeia), 123

Zedoary turmeric oil injection, 91
Zoonosis
caprylic acid, 495, 495
Salmonella enteritidis and Campylobacter jejuni, 495–6
WHO, 495